Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
AHCO.US
id: 857
AdaptHealth (AHCO) Deceptive Growth Claims Case
E.D. Pennsylvania
Court2:23-cv-04104
Case number04 Aug 2020
Class period Start27 Feb 2023
Class period End23 Dec 2023
Lead Plaintiff motion deadline- AdaptHealth claimed its growth was due to more clients and high demand for diabetes products. However, in reality, the growth was driven by improper billing practices.
- In February 2023, the truth came out, leading to a 27% $AHCO fall.
AdaptHealth claimed its exceptional growth was due to an expanding client base and a focus on supplying constantly needed diabetes products. They made statements about breaking records, citing Medicare relaxations as a contributing factor. In truth, AdaptHealth's growth was the result of improper billing practices.
On February 27, 2023, AdaptHealth reported a significant financial loss for the Q4 2022, contrary to the expected gain. Additionally, the company lowered its revenue expectations for 2023, blaming it on "lower diabetes growth."
This caused $AHCO fall by 27% and $815M loss of market cap the next day, damaging shareholders.
Given all the information, investors have reasons to suspect that AdaptHealth didn't disclose their financial condition and the real factors affecting it.
Case Status
Lead Plaintiff Appointed
Alleged Offence
Misleading Statements,
Failure to Disclose,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
28 February 2023
Filing date
24 October 2023
Lead Plaintiff Deadline
23 December 2023